Lenograstim

When ATH:
L03AA10

Pharmacological action.
Leukopoietic.

Application.

Neutropenia: after chemotherapy (primary and secondary prevention), Idiopathic, Congenital, cyclic, patients AIDS; neutropenic infection, intensification of chemotherapy, obtaining hematopoietic stem cells for future protection of hematopoiesis, prevention of infection after surgery, severe infection in non-cancer patients (in combination with antibiotics).

Contraindications.

Hypersensitivity, myeloproliferative disease, severe liver and kidney, pregnancy, breast-feeding.

Side effects.

Myalgia, ossalgia, fever, leukocytosis, thrombocytopenia, soreness at the injection site.

Dosing and Administration.

P /, I /, dose 19,2 million IU / m2, 1 once a day. The contents of the ampoule were dissolved in water for injection immediately before use; million IU / m 100 ml saline. million IU / m (to 28 days), to achieve and maintain the number of cells at the level of 10,000 / microliter within 3 days. To mobilize hematopoietic progenitor cells during chemotherapy, daily administration begins 24–48 hours after the last chemotherapeutic agent is discontinued.. In the treatment of severe infections in patients with a normal white blood cell count in adults - at a dose 33,6 In the treatment of severe infections in patients with a normal white blood cell count in adults - at a dose. For the prevention of infectious complications in plastic surgery on the esophagus: for 2 of the day before surgery and for a further 7 days thereafter.

Precautions.

The total duration of treatment with daily administration should not exceed 4 Sun. Showed regular monitoring of white blood cells and platelets in the peripheral blood. In the presence of marked leukocytosis (> 50In the treatment of severe infections in patients with a normal white blood cell count in adults - at a dose9 /l) We need a break. When bone pain or fever is recommended that a NSAID. Against the background of antitumor chemotherapy, the introduction of lenograstim is started 24-48 hours after the end of chemotherapy and is canceled on the last day before the start of the next course..

Cooperation

Active substanceDescription of interaction
MitomycinFMR. Against the background of lenograstima may increase bone marrow toxicity (especially the platelet germ).

Back to top button